Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin and cytarabine (Jazz Pharmaceuticals plc)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CPX-351 (Vyxeos) is a liposomal formulation of cytarabine and daunorubicin encapsulated in a fixed 5:1 molar ratio. This specific ratio has been shown in vitro to maximize synergistic antileukemic activity. The liposomal delivery system prolongs the half-life of the drugs and facilitates their uptake by bone marrow cells, particularly leukemia blasts, while reducing exposure to non-target tissues. Cytarabine acts as a pyrimidine analog that inhibits DNA polymerase, while daunorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II. It is FDA-approved for the treatment of adults and pediatric patients (1 year and older) with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicincytarabine-daunorubicin liposomeliposomal cytarabine-daunorubicin
02
Targets
DNA polymerase familyTOP2A (DNA topoisomerase II)POLG (Mitochondrial DNA polymerase gamma)CardiolipinTOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on daunorubicin and cytarabine (Jazz Pharmaceuticals plc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin and cytarabine (Jazz Pharmaceuticals plc).